我们的技术和生命科学团队为全球公司和快速发展的数字医疗行业的投资者提供无缝的专家建议。我们的客户是著名的投资者,从著名的早期基金到最大的全球风险投资公司,以及雄心勃勃的全球数字医疗公司,他们在我们的支持下,正在彻底改变行业。
通过我们已建立的投资者网络,我们在所有业务阶段为客户创造变革性的融资解决方案,为增长和持续发展创造坚实的财务基础。
凭借英国、欧洲、中东和亚洲的专家,以及我们在美国的主要合作伙伴,我们在提供金融和融资、监管和数据隐私以及知识产权方面的专业方法,加上跨境专业知识,为我们的客户提供了显著和可持续的全球扩张基础。我们对新兴数字医疗公司在内部和生态系统合作伙伴中面临的监管挑战的全面认识是非常宝贵的。
在我们的数据隐私和安全团队的支持下,我们成功解决了数字和基于应用的设备特有的个人数据问题,以及我们的客户在快速变化的行业中面临的更广泛的监管挑战。
同样,我们备受推崇的知识产权团队通过保卫、开发和保护宝贵的知识产权资产,帮助数字医疗公司达到了重要里程碑。这包括重组和执行复杂的协议和合作、伙伴关系和许可协议,以及通过战略并购收购和剥离有价值的业务。
Advised Protembis GmbH, the Aachen-based medical technology start-up, on financing by the European Investment Bank who granted the company a venture debt facility totalling EUR 20 million.
Press releaseAdvised Healx, an AI-enabled, clinical-stage biotech company specializing in rare diseases based in Cambridge UK, on its $47 million Series C funding. The funding was co-led by Silicon Valley-based R42 Group and Atomico, one of Europe’s largest venture capital firms, with participation from new and existing investors including Balderton, Jonathan Milner, Global Brain, btov, Ayana Capital, o2h and VU Venture Partners.
Press releaseAdvising Biomodal (formerly Cambridge Epigenetix) on its US$88 million Series D funding round to advance best-in-class DNA sequencing technology platform
Press releaseBabylon Health, a UK-based digital health subscription provider, on its USD550m fundraising to support expansion into the US and Asia. This is the largest ever fundraising in the European or US digital health sector and values Babylon at over USD2bn. Investors included PIF, ERGO Fund, Kinnevik and Vostok New Ventures.
Press release最新新闻和观点
EU and medicines supply issues (part one): Current measures
Marketing Authorisation Holders (MAHs) in the EU are legally required to report medicine supply shortages to the European Medicines Agency and national authorities. This article explores the central role of Marketing Authorisation Holders (MAHs) in identifying and managing medicine supply shortages in the EU as well as the role of EMA committees and working groups in coordinating responses and maintaining the Critical Medicines List to safeguard public health.
2 / 5 观点
EU and medicines supply issues (part two): Proposals for future measures
In part two of our article on EU and medicine supply issues we explore the key proposals outlined in pharmaceutical reform and their impact on marketing authorisation holders across the region.
作者 Alison Dennis 以及 Alice Matthews
3 / 5 观点
Guidance to manufacturers withdrawing a medical device from the EU market
Medical product availability and healthcare safety are becoming increasingly important talking points. This is also reflected in the EU regulations on medical devices. Although the provisions may seem straightforward their vagueness may give rise to significant doubts as to which situations they will apply to in practice.
4 / 5 观点
Comparison of national measures to protect the supply of medicines and medical devices
Our international team has developed a practical guide that allows users to navigate different European jurisdictions, identifying medicines subject to supply restrictions, and understand manufacturers' obligations during shortages or product withdrawals.
作者
5 / 5 观点